BCL2 and neoplasm: Interestingly, when we analyzed the BCL-2/MCL-1 ratio, predictive value of the observed ABT-263 efficacy (Figure 7C), we distinguished a parallelism between tumor growth and BCL-2/MCL-1 levels among sorafenib-only treated tumors (n=11).